BridgeBio Oncology Therapeutics, Inc (BBOT) Fair Value & Analysis
Healthcare · US · Market cap $610M
BridgeBio Oncology Therapeutics, Inc
BBOT · US
Fair value as of: Jul 14, 2026
From 1 valuation models · updated today
Share price +9.9% over the past month.
Price vs Fair Value (11 months)
11‑month range $7.12 – $13.73 · fair‑value band $2.72 – $5.15 · the $8.52 price screens above the $4.12 fair value. As of Jul 14, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
BridgeBio Oncology Therapeutics, Inc (BBOT) currently trades at $8.52, while our model-based Fair Value estimate is $4.12 — implying the stock looks roughly 51.6% overvalued today. We read business quality at 27/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
It earns a return on equity of -62.2%. The balance sheet holds a net cash position of $371M. Fundamentals as of Jul 14, 2026
Our scenario range runs from $2.72 (bear case) to $5.15 (bull case); at $8.52, the current price sits above that range. The share trades about 43% below its 52-week high and 22% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -32% fair-value upside — at -52%, BBOT screens richer than that median.
Key figures & financial health
Figures from reported company fundamentals (EODHD) · as of Jul 14, 2026. TTM = trailing twelve months.
About the company
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
BridgeBio Oncology Therapeutics, Inc reported revenue of $0 in FY2025 versus $0 in FY2023. Reported net income was −$134M in FY2025.
Is BBOT fairly valued? → Check now
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 14, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$562.61 | R$385.38 | -32% |
| Regeneron Pharmaceuticals, Inc REGN34 | R$52.30 | R$9.67 | -82% |
| UCB SA UCB | €274.90 | €211.40 | -23% |
| argenx SE ARGNF | $900.00 | $390.80 | -57% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,011,109 KRW | +1% |
| CSL Limited CSL | A$102.95 | A$126.79 | +23% |
| Celltrion, Inc 068270 | 167,300 KRW | 76,382 KRW | -54% |
| BioNTech SE B1NT34 | R$29.19 | R$21.38 | -27% |
| Moderna, Inc M1RN34 | R$12.44 | R$5.11 | -59% |
| Innovent Biologics, Inc 1801 | HK$85.35 | HK$21.13 | -75% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is BridgeBio Oncology Therapeutics, Inc (BBOT) undervalued?
What is the fair value of BBOT?
What is the quality score of BBOT?
What is the net profit margin of BBOT?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Unlock the full BridgeBio Oncology Therapeutics, Inc analysis — and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.